CTCBIO Inc. (KOSDAQ:060590)
4,440.00
-30.00 (-0.67%)
At close: Jan 29, 2026
CTCBIO Revenue
CTCBIO had revenue of 31.80B KRW in the quarter ending September 30, 2025, a decrease of -11.16%. This brings the company's revenue in the last twelve months to 132.76B, down -4.46% year-over-year. In the year 2024, CTCBIO had annual revenue of 144.41B with 4.74% growth.
Revenue (ttm)
132.76B
Revenue Growth
-4.46%
P/S Ratio
0.80
Revenue / Employee
535.32M
Employees
248
Market Cap
106.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 144.41B | 6.53B | 4.74% |
| Dec 31, 2023 | 137.88B | -27.33B | -16.54% |
| Dec 31, 2022 | 165.21B | 24.89B | 17.74% |
| Dec 31, 2021 | 140.32B | 10.29B | 7.91% |
| Dec 31, 2020 | 130.03B | -6.09B | -4.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 71.83B |
| Cell Biotech | 50.65B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 21.87B |
| BIO-FD&C | 18.82B |
| TegoScience | 6.15B |
| Quratis | 2.28B |
| Progen | 450.00M |